Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff
Executive Summary
Company had wanted accelerated approval for the antidote for all Factor Xa inhibitors, but will now focus the reversal agent on the two drugs commanding the largest markets – Bristol/Pfizer's Eliquis and J&J/Bayer's Xarelto.
You may also be interested in...
Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola
The latest drug development news and highlights from our FDA Performance Tracker.
Keeping Track: Janssen Gets A Breakthrough Therapy Status, FDA Awards Two Orphan Drug Designations, Portola Lands A CRL
The latest drug development news and highlights from our FDA Performance Tracker.
Barner Goes Out On A High As Boehringer Ingelheim Returns To Growth
Professor Dr Andreas Barner, the outgoing chief of Boehringer Ingelheim, was able to report a return to growth for the family-owned German company in 2015 at his final annual conference. The group was boosted by diabetes sales under its partnership with Eli Lilly & Co - as well as by the strength of the dollar. The company reports in euros but books nearly 40% of its sales in the US. With currency effects stripped out, the sales were up by a more modest 4.1% versus the 11.1% as reported.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: